Cardiac Failure Review最新文献

{"title":"Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition.","authors":"Davide Margonato,&nbsp;Simone Mazzetti,&nbsp;Renata De Maria,&nbsp;Marco Gorini,&nbsp;Massimo Iacoviello,&nbsp;Aldo P Maggioni,&nbsp;Andrea Mortara","doi":"10.15420/cfr.2020.13","DOIUrl":"https://doi.org/10.15420/cfr.2020.13","url":null,"abstract":"<p><p>The recent definition of an intermediate clinical phenotype of heart failure (HF) based on an ejection fraction (EF) of between 40% and 49%, namely HF with mid-range EF (HFmrEF), has fuelled investigations into the clinical profile and prognosis of this patient group. HFmrEF shares common clinical features with other HF phenotypes, such as a high prevalence of ischaemic aetiology, as in HF with reduced EF (HFrEF), or hypertension and diabetes, as in HF with preserved EF (HFpEF), and benefits from the cornerstone drugs indicated for HFrEF. Among the HF phenotypes, HFmrEF is characterised by the highest rate of transition to either recovery or worsening of the severe systolic dysfunction profile that is the target of disease-modifying therapies, with opposite prognostic implications. This article focuses on the epidemiology, clinical characteristics and therapeutic approaches for HFmrEF, and discusses the major determinants of transition to HFpEF or HFrEF.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e28"},"PeriodicalIF":0.0,"publicationDate":"2020-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/72/6c/cfr-06-e28.PMC7592465.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38561089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congestion and Diuretic Resistance in Acute or Worsening Heart Failure.","authors":"Ingibjörg Kristjánsdóttir,&nbsp;Tonje Thorvaldsen,&nbsp;Lars H Lund","doi":"10.15420/cfr.2019.18","DOIUrl":"https://doi.org/10.15420/cfr.2019.18","url":null,"abstract":"<p><p>Hospitalisation for acute heart failure (AHF) is associated with high mortality and high rehospitalisation rates. In the absence of evidence-based therapy, treatment is aimed at stabilisation and symptom relief. The majority of AHF patients have signs and symptoms of fluid overload, and, therefore, decongestion is the number one treatment goal. Diuretics are the cornerstone of therapy in AHF, but the treatment effect is challenged by diuretic resistance and poor diuretic response throughout the spectrum of chronic to worsening to acute to post-worsening HF. Adequate dosing and monitoring and evaluation of diuretic effect are important for treatment success. Residual congestion at discharge is a strong predictor of worse outcomes. Therefore, achieving euvolaemia is crucial despite transient worsening renal function.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e25"},"PeriodicalIF":0.0,"publicationDate":"2020-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/29/cfr-06-e25.PMC7539143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38479682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gone, but not Forgotten.","authors":"Barbara Pisani, Rahul Sharma","doi":"10.15420/cfr.2020.18","DOIUrl":"10.15420/cfr.2020.18","url":null,"abstract":"<p><p>The global health and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has rocked our communities and way of life. With millions infected around the globe, and hundreds of thousands of lives lost, there has been a paradigm shift in how clinicians evaluate and care for patients in multiple different types of healthcare settings. Many patients are reluctant to seek medical attention for cardiovascular illnesses, and late presentations of acute cardiac issues are raising the morbidity and mortality for treatable cardiac conditions. In this expert opinion, the authors canvas the many challenges in the diagnosis, treatment and delivery of care to patients with congestive heart failure and acute coronary syndromes during the COVID-19 pandemic.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e26"},"PeriodicalIF":0.0,"publicationDate":"2020-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/c3/cfr-06-e26.PMC7539141.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38479683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives.","authors":"Sebastian Rosch,&nbsp;Karl-Philipp Rommel,&nbsp;Markus Scholz,&nbsp;Holger Thiele,&nbsp;Philipp Lurz","doi":"10.15420/cfr.2019.19","DOIUrl":"https://doi.org/10.15420/cfr.2019.19","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e24"},"PeriodicalIF":0.0,"publicationDate":"2020-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/5e/cfr-06-e24.PMC7539142.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38479243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neprilysin as a Biomarker: Challenges and Opportunities.","authors":"Noemi Pavo,&nbsp;Suriya Prausmüller,&nbsp;Philipp E Bartko,&nbsp;Georg Goliasch,&nbsp;Martin Hülsmann","doi":"10.15420/cfr.2019.21","DOIUrl":"https://doi.org/10.15420/cfr.2019.21","url":null,"abstract":"<p><p>Neprilysin (NEP) inhibition is a successful novel therapeutic approach in heart failure with reduced ejection fraction. Assessing individual NEP status might be important for gathering insights into mechanisms of disease and optimising individualised patient care. NEP is a zinc-dependent multisubstrate-metabolising oligoendopeptidase localised in the plasma membrane with the catalytic site facing the extracellular space. Although NEP activity in vivo is predominantly tissue-based, NEP can be released into the circulation via ectodomain shedding and exosomes. Attempts to determine circulating NEP concentrations and activity have not yet resulted in convincingly coherent results relating NEP biomarkers to heart failure disease severity or outcomes. NEP is naturally expressed on neutrophils, opening up the possibility of measuring a membrane-associated form with integrity. Small studies have linked NEP expression on neutrophils with inflammatory state and initial data might indicate its role in heart failure with reduced ejection fraction. Future studies need to assess the regulation of systemic NEP activity, which is assumed to be tissue-based, and the relationship of NEP activation with disease state. The relationship between tissue NEP activity and easily accessible circulating NEP biomarkers and the impact of the latter remains to be established.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e23"},"PeriodicalIF":0.0,"publicationDate":"2020-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/87/cfr-06-e23.PMC7479538.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38394500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronavirus Disease 2019 and Heart Failure: A Multiparametric Approach.","authors":"Estefania Oliveros, Yevgeniy Brailovsky, Paul Scully, Evgenia Nikolou, Ronak Rajani, Julia Grapsa","doi":"10.15420/cfr.2020.09","DOIUrl":"10.15420/cfr.2020.09","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) is a debilitating viral infection and, to date, 628,903 people have died from it, numbers that cannot yet be compared to the 50 million who died in the 1918 flu pandemic. As COVID-19 became better understood, cardiovascular manifestations associated with it were identified. This led to a complete healthcare restructuring with virtual clinics and changes to the triaging of critically ill patients. There are a lot of questions over how COVID-19 affects patients with heart failure (HF) as this condition is a leading cause of cardiovascular death. This review describes the cardiovascular implications of COVID-19 and new practices surrounding the use of telehealth to follow up and triage patients with HF. Current practices supported by medical societies, the role of angiotensin-converting enzyme inhibitors and, finally, a brief note regarding the management of advanced HF patients will also be discussed.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e22"},"PeriodicalIF":4.2,"publicationDate":"2020-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/7d/cfr-06-e22.PMC7479531.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38394499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?","authors":"Sebastiaan Hc Klaassen,&nbsp;Dirk J van Veldhuisen,&nbsp;Hans LA Nienhuis,&nbsp;Maarten P van den Berg,&nbsp;Bouke Pc Hazenberg,&nbsp;Peter van der Meer","doi":"10.15420/cfr.2019.16","DOIUrl":"https://doi.org/10.15420/cfr.2019.16","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis. This article reviews the clinical characteristics of cardiac ATTR amyloidosis. The clinical suspicion of cardiac ATTR amyloidosis is strong if pronounced left ventricular hypertrophy is present in the absence of hypertension. Scintigraphy with a diphosphonate tracer is a diagnostic tool for the early detection of cardiac ATTR amyloidosis with high sensitivity and specificity. First treatment options for ATTR amyloidosis recently emerged, and showed a reduction in morbidity and mortality, especially if treatment was started in the early stages of disease. In light of these results, screening for ATTR amyloidosis in the general HFpEF population with left ventricular hypertrophy might be useful.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e21"},"PeriodicalIF":0.0,"publicationDate":"2020-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/ee/cfr-06-e21.PMC7479537.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38394498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morphine in the Setting of Acute Heart Failure: Do the Risks Outweigh the Benefits?","authors":"Oren Caspi,&nbsp;Doron Aronson","doi":"10.15420/cfr.2019.22","DOIUrl":"https://doi.org/10.15420/cfr.2019.22","url":null,"abstract":"<p><p>The use of opioids in acute pulmonary oedema is considered standard therapy by many physicians. The immediate relieving effect of morphine on the key symptomatic discomfort associated with acute heart failure, dyspnoea, facilitated the categorisation of morphine as a beneficial treatment in this setting. During the last decade, several retrospective studies raised concerns regarding the safety and efficacy of morphine in the setting of acute heart failure. In this article, the physiological effects of morphine on the cardiovascular and respiratory systems are summarised, as well as the potential clinical benefits and risks associated with morphine therapy. Finally, the reported clinical outcomes and adverse event profiles from recent observational studies are discussed, as well as future perspectives and potential alternatives to morphine in the setting of acute heart failure.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e20"},"PeriodicalIF":0.0,"publicationDate":"2020-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/ac/cfr-06-e20.PMC7407569.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38246444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.","authors":"Zoltán Papp,&nbsp;Piergiuseppe Agostoni,&nbsp;Julian Alvarez,&nbsp;Dominique Bettex,&nbsp;Stefan Bouchez,&nbsp;Dulce Brito,&nbsp;Vladimir Černý,&nbsp;Josep Comin-Colet,&nbsp;Marisa G Crespo-Leiro,&nbsp;Juan F Delgado,&nbsp;Istvan Édes,&nbsp;Alexander A Eremenko,&nbsp;Dimitrios Farmakis,&nbsp;Francesco Fedele,&nbsp;Cândida Fonseca,&nbsp;Sonja Fruhwald,&nbsp;Massimo Girardis,&nbsp;Fabio Guarracino,&nbsp;Veli-Pekka Harjola,&nbsp;Matthias Heringlake,&nbsp;Antoine Herpain,&nbsp;Leo Ma Heunks,&nbsp;Tryggve Husebye,&nbsp;Višnja Ivancan,&nbsp;Kristjan Karason,&nbsp;Sundeep Kaul,&nbsp;Matti Kivikko,&nbsp;Janek Kubica,&nbsp;Josep Masip,&nbsp;Simon Matskeplishvili,&nbsp;Alexandre Mebazaa,&nbsp;Markku S Nieminen,&nbsp;Fabrizio Oliva,&nbsp;Julius-Gyula Papp,&nbsp;John Parissis,&nbsp;Alexander Parkhomenko,&nbsp;Pentti Põder,&nbsp;Gerhard Pölzl,&nbsp;Alexander Reinecke,&nbsp;Sven-Erik Ricksten,&nbsp;Hynek Riha,&nbsp;Alain Rudiger,&nbsp;Toni Sarapohja,&nbsp;Robert Hg Schwinger,&nbsp;Wolfgang Toller,&nbsp;Luigi Tritapepe,&nbsp;Carsten Tschöpe,&nbsp;Gerhard Wikström,&nbsp;Dirk von Lewinski,&nbsp;Bojan Vrtovec,&nbsp;Piero Pollesello","doi":"10.15420/cfr.2020.03","DOIUrl":"https://doi.org/10.15420/cfr.2020.03","url":null,"abstract":"<p><p>Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced heart failure, right ventricular failure and pulmonary hypertension, cardiac surgery, critical care and emergency medicine. Levosimendan is currently in active clinical evaluation in the US. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, UK and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute heart failure arena in recent times and charts a possible development trajectory for the next 20 years.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e19"},"PeriodicalIF":0.0,"publicationDate":"2020-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d5/be/cfr-06-e19.PMC7374352.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38203091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronavirus Disease 2019: Where are we and Where are we Going? Intersections Between Coronavirus Disease 2019 and the Heart.","authors":"Emilia D'Elia,&nbsp;Michele Senni","doi":"10.15420/cfr.2020.11","DOIUrl":"https://doi.org/10.15420/cfr.2020.11","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which has become a pandemic affecting every country in the world. In the province of Bergamo, Italy, more than 2,200 cases of COVID-19 have been reported, which include more than 300 deaths. Most hospitalisations have been at the Papa Giovanni XXIII Hospital. This has imposed a significant burden on our hospital in terms of healthcare personnel, dedicated spaces (including intensive care areas) and time spent by clinicians, who are committed to assisting COVID-19 patients. In this short expert opinion, the authors will focus on new insights related to COVID-19 and the cardiovascular system, and try to investigate the grey areas and uncertainties in this field.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e18"},"PeriodicalIF":0.0,"publicationDate":"2020-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/24/cfr-06-e18.PMC7341260.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38164613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}